Q2 FY25 Earnings Presentation May 1, 2025 Advancing the world of healthTM Q2 FY25 EARNINGS PRESENTATION MAY 1, 2025 2 Basis of Presentation All dollar amounts presented are USD ($) in millions, unless otherwise indicated, except per share figures. FXN denotes currency-neutral basis. Revenue year-over-year change comparisons are on an FXN basis unless otherwise noted. Caution Concerning Forward-looking Statements This presentation and accompanying webcast contain certain estimates and other forward-looking s ...

Becton Dickinson and Company (BDX) , popularly known as BD, is scheduled to report second-quarter fiscal 2025 results on May 1, before market open.In the last reported quarter, the company’s earnings per share (EPS) of $3.43 surpassed the Zacks Consensus Estimate by 15.1%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 7.3%, on average. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Let’s che ...

碧迪医疗业务分拆计划 - 公司宣布将生物科学与诊断解决方案业务从主体业务中分拆，转型为纯医疗器械公司[1] - 被剥离业务2024财年收入达12.8亿美元(约93.2亿人民币)，占公司总收入25.7%[1][10] - 分拆后新BD预计年收入178亿美元，目标市场价值超700亿美元[1][4] 分拆战略背景 - 此次分拆是继糖尿病部门Embecta剥离后的第二次重大业务重组[3] - 旨在通过增强战略聚焦和优化资本配置释放股东价值[1] - 预计2025财年末公布具体细节，2026财年完成交易[1] 新BD业务架构 - 将形成四大业务板块：医疗基础(年收入62亿美元)、互联护理(43亿美元)、生物制药系统(23亿美元)、介入治疗(50亿美元)[31] - 各板块对应市场规模分别为170亿/70亿/180亿/270亿美元，预计增长率3-9%不等[9] - 90%以上为经常性收入，目标年增长率5%[4] 生物科学与诊断业务 - 包含流式细胞仪(BD FACS系列)、微生物检测(BD BACTEC)和分子诊断(BD COR)三大产品线[16] - 在免疫学、癌症研究和临床诊断领域保持领先地位[10] - 拥有18种新型流式细胞试剂和HPV初筛检测等创新产品储备[16] 财务表现与展望 - 公司2024财年总收入201.78亿美元，调整后收入202.45亿美元[51] - 2025财年指引：预计收入217-219亿美元，有机增长4-4.5%[51] - 基础调整后每股收益预计14.3-14.6美元，同比增长8.8-11%[52]